MaxCyte, Inc. (MXCT)
1.61
+0.01
(+0.62%)
USD |
NASDAQ |
Dec 26, 16:00
1.61
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 171.75M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -60.44% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.964 |
| Price to Book Value | 0.9527 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1007 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 92.62% |
Profile
| MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD. |
| URL | http://www.maxcyte.com |
| Investor Relations URL | https://investors.maxcyte.com/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 17, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD. |
| URL | http://www.maxcyte.com |
| Investor Relations URL | https://investors.maxcyte.com/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 17, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |